Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study

Joerger, M; Hundsberger, T; Haefliger, S; von Moos, R; Hottinger, AF; Kaindl, T; Engelhardt, M; Marszewska, M; Lane, H; Roth, P; Stathis, A

Kaindl, T (通讯作者)，Basilea Pharmaceut Int Ltd, Hegenheimermattweg 167b, CH-4123 Allschwil, Switzerland.

INVESTIGATIONAL NEW DRUGS, 2023; 41 (2): 267

Abstract

Purpose. Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent. The goal of this study (NCT02895360) was ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索